Biotech Company with Groundbreaking Technology
January 07 2015 - 9:00AM
InvestorsHub NewsWire
USOTC: PPCH
Propanc Health Group Has Unique
Anti-Metastasic Drug
Propanc Health Group Corp., a biopharmaceutical company
organized in Melbourne, Australia, in 2007, has developed a unique
drug for the treatment of many types of cancer specifically
targeting the process of metastasis. Targeted therapies for
metastatic cancer has long been regarded as an important goal in
cancer research, as metastasis is the cause of most cancer-related
deaths and as no currently approved cancer therapies target
metastasis.
Most types of cancer – specifically those that initially arise
as solid tumors – develop over long periods of time, remaining
non-malignant or at least relatively treatable if identified at
this early stage. Cancer becomes far more serious and difficult to
treat when it spreads to new locations within the body. This
process, called metastasis, is dangerous for a number
of reasons. For one, it leads to the establishment of tumors in
organs where simple surgical removal may not be possible. Tumors
that begin in the skin, for example, can be easily removed if
caught early, but metastases that end up in the lungs or the brain
or anywhere near a large blood vessel can be dangerous to approach
surgically.
Even more importantly, once a tumor has been found to spread to
one site, it has very likely spread to many sites already. In these
cases, simple surgical removal of one of the metastatic tumor is
not nearly enough to deal with the spread. And metastatic tumors
are often difficult to define clearly – tumors that start out as
well-defined lumps are often diffuse and deeply integrated into the
tissue when they are metastatic, again making them hard to approach
surgically.
Finally, metastatic tumors have other qualities that make them
more dangerous than primary tumors. Tumors that arise in skin, for
example, maintain some of the qualities of skin cells for a time,
but if they progress toward metastasis, they have typically
acquired the qualities of the less well defined cells that normally
live in places below the skin or below the surfaces of organs
called mesenchymal cells. This transition from the
qualities of epithelial (skin-like) cells to
mesenchymal cells, also referred to as an epithelial to
mesenchymal transition (EMT), has long been recognized as
a general feature of the development of many types of cancer.
Scientists have documented characteristic changes in the surfaces
of these cells that are associated with the epithelial to
mesenchymal transition, which includes the loss of a protein that
normally allows these cells to stick tightly together, as in skin.
This molecule, called E-cadherin, is a normal part of all skin
cells and many other cell types that line the surfaces of
organs.
Propanc has developed a blend of naturally-occurring chemicals –
PRP – that has now been shown to specifically block or reverse the
processes that lead to the development of metastases and their
ability to grow and spread further. These chemicals, or proenzymes,
are normally manufactured by the pancreas. In fact, the company
name Propanc is derived from the words "proenzyme" and "pancreas".
In tests on cancer cells, PRP was able to halt the growth of cancer
cells and cause these cells to undergo cell death. It was also able
to reverse the process of epithelial to mesenchymal transition, as
indicated by specific changes in the proteins made by these cells,
including the critical protein E-cadherin. Finally, PRP was also
able to cause malignant cancer cells to transition to more harmless
cell types, no longer cancerous. All three of these changes in
cancer cells caused by PRP indicate that PRP may be highly
effective in the treatment of metastatic cancers of many types. The
results of these studies have been published in the peer-reviewed
scientific journal Cellular Oncology in July, 2013.
What makes these findings particularly important is that there
are currently no FDA-approved drugs specifically targeting
metastatic cancer, yet without metastasis, most cancers would not
be serious or
fatal. Most chemical and radiological therapies for cancer are
nonspecific, targeting all growing cells and therefore limiting
their usefulness due to the inherent toxicity to normal cells. The
demand for more targeted and less toxic drugs that specifically
target metastasis is therefore enormous. Propanc has tremendous
potential to change this market upon approval of PRP. It not only
specifically targets metastatic cancer cells and the process of
metastasis, it is composed of chemicals naturally occurring in the
human body and therefore lacking intrinsic toxicity to humans. This
means that PRP could be used in a very high dose range, as needed
for maximum effectiveness. It would also be less likely to exhibit
toxic interactions when used in combination with other drugs.
The anti-tumor action of PRP can also be enhanced through the
use of adjuncts that further enhance the tumor-killing properties
of PRP. The Propanc formulation PRP-DCM adds well-studied
chemotherapeutic agents that help to starve tumors of oxygen and
increase the rate at which they undergo cell death.
Propanc is a forward-looking company that seeks to answer the
large and growing demand for affordable, accessible, and easy to
administer anti-cancer therapies. Propanc has developed a targeted
anticancer therapeutic with the potential to extend survival among
those patients with more advanced forms of cancer involving
metastasis; currently, there are no drugs approved for the
targeting of metastatic cancer, placing Propanc in a strong
position as the regulatory process moves forward.
As a sector of the anti-cancer market, drugs targeting
metastasis have not yet matured, and investors are not yet aware of
its central importance for cancer therapy and its growth potential.
Therefore, Propanc is currently likely to be highly undervalued as
an investment.
Similar Companies to Propanc Health Group Corp. ( PPCH ) that
are listed on major exchanges include:
Pluristem Therapeutics Inc. is a clinical-stage biotechnology company using
placental cells and a unique, proprietary, three-dimensional (3D)
technology platform to develop cell therapies for a broad spectrum
of diseases.
AEterna Zentaris Inc. is
a specialty biopharmaceutical company engaged in developing and
commercializing novel treatments in oncology, endocrinology and
women's health. The Company's pipeline encompasses compounds at
various stages of development.
CTI BioPharma Corp. is
a biopharmaceutical company whose mission is to acquire, develop
and bring to market less toxic, more effective therapies to treat
and cure cancer.
About regalconsultingllc.com
RegalConsultingLLC.com is a leading independent research,
advisory and consulting firm serving Investors,
Publicly Traded Companies, Private Companies and The Financial
Community.
Legal Disclaimer
Except for the historical information presented herein, matters
discussed in this article contain forward-looking statements that
are subject to certain risks and uncertainties that could cause
actual results to differ materially from any future results,
performance or achievements expressed or implied by such
statements. Regal Consulting, LLC which owns www.RegalConsultingLLC.com, is not registered
with any financial or securities regulatory authority, and does not
provide nor claims to provide investment advice or recommendations
to readers of this release. Regal Consulting, LLC. which
owns www.RegalConsultingLLC.com, may from time to
time have a position in the securities mentioned herein and may
increase or decrease such positions without notice. For making
specific investment decisions, readers should seek their own
advice. Regal Consulting, LLC. which owns www.RegalConsultingLLC.com, may be compensated
for its services in the form of cash-based compensation or equity
securities in the companies it writes about, or a combination of
the two.
Contact Information:
RegalConsultingLLC.com
702-575-9157
RegalConsutlingLLC@gmail.com
SOURCE: RegalConsultingLLC.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024